On Friday, pharmaceutical firm Novo Nordisk settled a securities lawsuit in which shareholders had alleged Novo Nordisk had misled them about the insulin sales pressure on the US market and what this would mean for future sales.
The settlement contained no admission of wrongdoing on Novo Nordisk's part, and no payment to the plaintiffs will be made by the company.
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.